Health Catalyst, Inc. (HCAT) Bundle
Understanding Health Catalyst, Inc. (HCAT) Revenue Streams
Understanding Health Catalyst, Inc. (HCAT) Revenue Streams
Revenue Breakdown
- Technology Revenue: For the nine months ended September 30, 2024, technology revenue was $143.3 million, compared to $140.5 million for the same period in 2023.
- Professional Services Revenue: Professional services revenue for the nine months ended September 30, 2024, was $83.7 million, compared to $80.4 million in 2023.
- Total Revenue: Total revenue for the nine months ended September 30, 2024, was $226.9 million, an increase from $220.9 million in 2023.
Year-over-Year Revenue Growth Rate
- Technology Segment Growth: The technology segment saw a year-over-year increase of 1.7%.
- Professional Services Segment Growth: The professional services segment experienced a year-over-year increase of 4.2%.
- Total Revenue Growth: Overall revenue grew by 2.7% year-over-year.
Contribution of Different Business Segments to Overall Revenue
| Segment | Revenue (2024) | Revenue (2023) | Percentage of Total Revenue (2024) | Percentage of Total Revenue (2023) |
|---|---|---|---|---|
| Technology | $143.3 million | $140.5 million | 63.1% | 63.6% |
| Professional Services | $83.7 million | $80.4 million | 36.9% | 36.4% |
Analysis of Significant Changes in Revenue Streams
- New Client Acquisition: Revenue growth was primarily driven by an increase in new clients and expansion from existing clients.
- Cost Management: Professional services gross margin increased from 8% for the nine months ended September 30, 2023, to 14% for the same period in 2024.
- Adjusted Gross Profit: Adjusted gross profit for the nine months ended September 30, 2024, was $112.4 million, compared to $109.4 million in 2023.
Revenue by Type of Arrangement
| Type of Arrangement | Q3 2024 Revenue | Q3 2023 Revenue | 9M 2024 Revenue | 9M 2023 Revenue |
|---|---|---|---|---|
| Recurring Technology | $48.7 million | $46.0 million | $143.3 million | $140.1 million |
| One-time Technology | $0 | $0 | $0 | $0.4 million |
| Professional Services | $27.7 million | $27.8 million | $83.7 million | $80.4 million |
Conclusion
- Revenue Growth Factors: Continued investment in technology and strategic shifts towards high-margin services have positively influenced revenue growth.
- Market Demand: The healthcare sector's increasing reliance on data and analytics has strengthened demand for both technology and professional services.
A Deep Dive into Health Catalyst, Inc. (HCAT) Profitability
A Deep Dive into Health Catalyst, Inc.'s Profitability
Gross Profit, Operating Profit, and Net Profit Margins
For the nine months ended September 30, 2024, total revenue was $226.978 million, with a gross profit of $85.885 million, resulting in a gross margin of 38%. The operating loss for the same period was $52.306 million, leading to a net loss of $48.829 million, translating to a net loss margin of (21.5%) .
Trends in Profitability Over Time
Comparing the nine months ended September 30, 2024, to the same period in 2023, total revenue increased by $6.124 million or 3%. Gross profit increased from $80.100 million in 2023 to $85.885 million in 2024. However, the net loss decreased from $87.835 million in 2023 to $48.829 million in 2024 .
Comparison of Profitability Ratios with Industry Averages
As of 2024, the gross margin of 38% aligns with the industry average of approximately 40% for healthcare technology firms. The operating margin was significantly lower than the industry average of around 10%, indicative of the company's ongoing investment in growth and restructuring efforts .
Analysis of Operational Efficiency
The total cost of revenue for the nine months ended September 30, 2024, was $120.890 million, with technology costs at $48.991 million and professional services costs at $71.899 million. The percentage of total revenue attributed to costs has remained stable at 54% .
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenue | $76.353 million | $73.773 million | $2.580 million (3.5%) |
| Gross Profit | $27.758 million | $25.339 million | $2.419 million (9.5%) |
| Operating Loss | $13.687 million | $24.580 million | $10.893 million (44.3%) |
| Net Loss | $14.726 million | $22.032 million | $7.306 million (33.2%) |
| Gross Margin | 36% | 34% | 2% increase |
| Adjusted Gross Margin | 48% | 47% | 1% increase |
In the nine months ended September 30, 2024, the adjusted gross margin remained constant at 50%. The operational efficiency is reflected in the reduction of operating expenses from $195.437 million in 2023 to $158.394 million in 2024 .
The professional services segment demonstrated improved profitability, with gross margins increasing from 8% for the nine months ended September 30, 2023, to 14% for the same period in 2024. This improvement is attributed to enhanced utilization rates and effective cost management strategies .
Debt vs. Equity: How Health Catalyst, Inc. (HCAT) Finances Its Growth
Debt vs. Equity: How Health Catalyst, Inc. Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, the total principal outstanding of the company's debt was $355 million, which includes:
- $230 million in 2.50% convertible senior notes due 2025
- $125 million in a variable interest rate term loan maturing in 2029
The net carrying amount of the debt, after accounting for unamortized discounts and issuance costs, was $345.034 million.
Debt-to-Equity Ratio and Comparison to Industry Standards
The company's total liabilities as of September 30, 2024, were $458.013 million, and total stockholders' equity was $355.037 million. This results in a debt-to-equity ratio of approximately 1.29, which is higher than the industry average of about 0.5 for healthcare technology companies.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
In July 2024, the company entered into a credit agreement with Silver Point Finance, which provided a five-year term loan facility totaling $225 million. This included an initial term loan of $125 million fully funded at closing, and a delayed draw facility of up to $100 million.
How the Company Balances Between Debt Financing and Equity Funding
The company has actively utilized equity funding alongside debt financing. As of September 30, 2024, the total common stock and additional paid-in capital amounted to $1.521 billion, with an accumulated deficit of $1.166 billion. The company’s strategy includes leveraging its equity to maintain balance sheet flexibility while managing debt levels.
| Debt Component | Amount (in thousands) | Maturity Date |
|---|---|---|
| Convertible Senior Notes | $230,000 | 2025 |
| Variable Interest Rate Term Loan | $125,000 | 2029 |
| Total Principal Outstanding | $355,000 | N/A |
| Net Carrying Amount | $345,034 | N/A |
With these financial structures, the company is positioned to navigate the complexities of the healthcare market while pursuing growth opportunities in its sector. The balance of debt and equity financing plays a crucial role in supporting its operational and strategic objectives.
Assessing Health Catalyst, Inc. (HCAT) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
As of September 30, 2024, the current ratio for the company stood at 6.12, indicating a strong liquidity position. This is calculated from current assets of $387.3 million and current liabilities of $63.4 million. The quick ratio, which excludes inventory from current assets, is approximately 6.10.
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is $323.9 million, reflecting an increase from $290.4 million at the end of 2023. This trend suggests improving operational efficiency and better management of short-term assets and liabilities.
Cash Flow Statements Overview
Operating Cash Flow Trends
For the nine months ended September 30, 2024, the net cash provided by operating activities was $18.1 million, compared to a cash outflow of $14.0 million for the same period in 2023.
Investing Cash Flow Trends
Net cash used in investing activities for the nine months ended September 30, 2024, was $89.8 million, with significant expenditures on acquisitions totaling $54.9 million and purchases of short-term investments at $50.2 million.
Financing Cash Flow Trends
In the financing activities, net cash provided was $114.1 million for the same period, reflecting proceeds from long-term debt issuance of $115.5 million and minimal share repurchases.
| Cash Flow Activities | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Operating Activities | $18,086 | ($14,039) |
| Investing Activities | ($89,847) | ($9,624) |
| Financing Activities | $114,056 | $2,335 |
Potential Liquidity Concerns or Strengths
Despite the strong liquidity ratios, the company faces potential liquidity concerns due to its reliance on debt financing, with total debt amounting to $355.0 million as of September 30, 2024. The interest expense has increased to $9.8 million for the nine months ended September 30, 2024, up from $5.5 million in the same period in 2023.
The company's cash, cash equivalents, and short-term investments of $387.3 million are expected to meet working capital needs for at least the next 12 months, although additional financing may be required in the future.
Is Health Catalyst, Inc. (HCAT) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will analyze key financial ratios, stock price trends, dividend yield, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current P/E ratio is – (negative earnings indicate no P/E ratio). The company reported a net loss of $14.7 million for the three months ended September 30, 2024.
Price-to-Book (P/B) Ratio
The latest book value per share is $5.85 as of September 30, 2024, with total stockholders' equity of $355.0 million and shares outstanding of 60.8 million. The current stock price is approximately $8.00, resulting in a P/B ratio of 1.36.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The company reported an Adjusted EBITDA of $7.3 million for the three months ended September 30, 2024. The enterprise value, considering a market cap of approximately $486.4 million and total debt of $355.0 million, leads to an EV/EBITDA ratio of approximately 66.5.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated as follows:
| Month | Stock Price |
|---|---|
| September 2023 | $11.00 |
| December 2023 | $9.50 |
| March 2024 | $7.25 |
| June 2024 | $8.50 |
| September 2024 | $8.00 |
Dividend Yield and Payout Ratios
No dividends have been declared or paid on common stock through September 30, 2024.
Analyst Consensus on Stock Valuation
Analyst consensus indicates a rating of Hold based on current valuation metrics and market performance.
Key Risks Facing Health Catalyst, Inc. (HCAT)
Key Risks Facing Health Catalyst, Inc.
Health Catalyst, Inc. faces a variety of internal and external risks that could impact its financial health. These risks range from industry competition to regulatory changes and fluctuating market conditions.
Industry Competition
The healthcare technology sector is highly competitive, with numerous players vying for market share. As of September 30, 2024, the company reported a net loss of $14.7 million for the three months ended September 30, 2024, compared to a loss of $22.0 million for the same period in 2023. This indicates a challenging environment in which competition could further pressure margins and customer retention.
Regulatory Changes
Changes in healthcare regulations can significantly impact operations. The company operates in a heavily regulated industry, and any changes to regulations could lead to increased compliance costs or affect the demand for its services. The nine-month period ending September 30, 2024, saw a revenue increase to $227.0 million from $220.9 million in the prior year, but regulatory headwinds could hamper future growth.
Market Conditions
The macroeconomic environment, characterized by high inflation and interest rates, has adversely affected the healthcare sector. The company noted that its clients have experienced significant increases in labor and supply costs without a corresponding increase in revenue, leading to deterioration in operating margins. This market pressure is reflected in the company's Dollar-based Retention Rate, which they expect to improve in 2024 but remains a concern due to the current economic climate.
Operational Risks
Operational challenges include the integration of new technologies and the management of costs associated with transitioning clients to new platforms. The company has reported a total gross margin increase from 36% for the nine months ended September 30, 2023, to 38% for the same period in 2024. However, they expect fluctuations in gross margins due to anticipated growth in professional services, which may affect profitability.
Financial Risks
Financial risks are highlighted by the company's reliance on debt. As of September 30, 2024, the company had $355 million in total principal outstanding, which includes $230 million in convertible senior notes due in 2025. The pressure to meet these obligations could strain the company's cash flows, particularly if revenue growth does not meet expectations.
Strategic Risks
The company has undergone significant restructuring, resulting in a cumulative charge of $8.855 million related to its 2023 Restructuring Plan. While this strategy aims to optimize costs, ongoing execution risks remain, particularly in ensuring that the workforce reductions do not negatively impact service delivery or client satisfaction.
Mitigation Strategies
To address these risks, the company has implemented several strategies, including a focus on operational efficiency and investments in research and development. As of September 30, 2024, Adjusted EBITDA improved to $7.3 million from $2.0 million in the previous year. This improvement is a positive indicator of the effectiveness of their cost management efforts and operational adjustments.
| Risk Factor | Description | Impact | Mitigation Strategy |
|---|---|---|---|
| Industry Competition | Numerous players in the healthcare tech sector | Pressure on margins and customer retention | Focus on innovation and customer service |
| Regulatory Changes | Healthcare regulations can affect operations | Increased compliance costs | Proactive compliance management |
| Market Conditions | High inflation and interest rates | Deterioration in client operating margins | Cost management and pricing strategies |
| Operational Risks | Challenges in technology integration | Fluctuations in profitability | Streamlining operations |
| Financial Risks | Reliance on debt financing | Strain on cash flows | Improving cash flow through revenue growth |
| Strategic Risks | Ongoing execution risks from restructuring | Impact on service delivery | Regular assessment of restructuring outcomes |
Future Growth Prospects for Health Catalyst, Inc. (HCAT)
Future Growth Prospects for Health Catalyst, Inc.
Analysis of Key Growth Drivers
The company is poised for growth driven by several key factors:
- Product Innovations: Introduction of the Health Catalyst Ignite platform, enabling modular and scalable solutions for clients.
- Market Expansions: Ongoing migration of existing clients to the Ignite platform, expected to increase revenue predictability.
- Acquisitions: Strategic acquisitions such as ARMUS and KPI Ninja contribute to expanding service offerings and client base.
Future Revenue Growth Projections
For the year ending December 31, 2024, revenue projections are as follows:
- Total Revenue: Expected between $400 million and $500 million.
- Adjusted EBITDA: Anticipated to reach approximately $25 million.
| Metric | 2024 Estimate | 2023 Actual |
|---|---|---|
| Total Revenue | $400 million - $500 million | $220.9 million |
| Adjusted EBITDA | $25 million | $9.7 million |
| Net Loss | $48.8 million | $87.8 million |
Strategic Initiatives or Partnerships
Key strategic initiatives include:
- Partnerships: Collaborations with healthcare organizations to enhance service delivery and data analytics capabilities.
- Innovation Investments: Increased R&D investments in technology enhancements and service offerings.
Competitive Advantages
The company benefits from several competitive advantages that position it for future growth:
- Recurring Revenue Model: Over 90% of revenue is recurring, providing stability and predictability.
- Scalability of Solutions: The Ignite platform's modularity allows for tailored solutions that meet diverse client needs.
- Strong Client Relationships: Established relationships with existing clients facilitate cross-selling and upselling opportunities.
Market Trends and Conditions
The current macroeconomic environment presents both challenges and opportunities:
- Macroeconomic Challenges: High inflation and labor costs impacting client budgets.
- Market Recovery: Stabilizing operating margins observed for clients, suggesting potential for increased spending on technology solutions.
Health Catalyst, Inc. (HCAT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Health Catalyst, Inc. (HCAT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Health Catalyst, Inc. (HCAT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Health Catalyst, Inc. (HCAT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.